Castle Biosciences Stock Analysis
CSTL Stock | USD 27.09 0.57 2.15% |
Castle Biosciences is undervalued with Real Value of 30.91 and Target Price of 33.0. The main objective of Castle Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Castle Biosciences is worth, separate from its market price. There are two main types of Castle Biosciences' stock analysis: fundamental analysis and technical analysis.
The Castle Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Castle |
Castle Stock Analysis Notes
About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.68. Some equities with similar Price to Book (P/B) outperform the market in the long run. Castle Biosciences had not issued any dividends in recent years. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. The company was founded in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 482 people. For more info on Castle Biosciences please contact Derek Maetzold at 866 788 9007 or go to https://castlebiosciences.com.Castle Biosciences Quarterly Total Revenue |
|
Castle Biosciences Investment Alerts
Castle Biosciences generated a negative expected return over the last 90 days | |
Castle Biosciences has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 219.79 M. Net Loss for the year was (57.47 M) with profit before overhead, payroll, taxes, and interest of 105.03 M. | |
Castle Biosciences currently holds about 273.17 M in cash with (5.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.39. | |
Castle Biosciences has a poor financial position based on the latest SEC disclosures | |
Over 95.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from zacks.com: SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder |
Castle Biosciences Upcoming and Recent Events
27th of February 2024 Upcoming Quarterly Report | View | |
1st of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Castle Largest EPS Surprises
Earnings surprises can significantly impact Castle Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.12 | -0.17 | -0.05 | 41 | ||
2021-05-10 | 2021-03-31 | -0.23 | -0.17 | 0.06 | 26 | ||
2021-11-08 | 2021-09-30 | -0.4 | -0.47 | -0.07 | 17 |
Castle Biosciences Environmental, Social, and Governance (ESG) Scores
Castle Biosciences' ESG score is a quantitative measure that evaluates Castle Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Castle Biosciences' operations that may have significant financial implications and affect Castle Biosciences' stock price as well as guide investors towards more socially responsible investments.
Castle Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Nuveen Asset Management, Llc | 2024-09-30 | 542.6 K | Palisade Capital Management Llc | 2024-09-30 | 502.3 K | Point72 Asset Management, L.p. | 2024-09-30 | 499.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 496.5 K | Renaissance Technologies Corp | 2024-09-30 | 489.6 K | Granahan Investment Management Inc.. | 2024-09-30 | 425.2 K | Kornitzer Capital Management Inc | 2024-09-30 | 407.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 396.9 K | Ameriprise Financial Inc | 2024-09-30 | 349.2 K | Blackrock Inc | 2024-06-30 | 3 M | Wasatch Advisors Lp | 2024-09-30 | 1.8 M |
Castle Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 758.72 M.Castle Profitablity
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.17) | (0.18) | |
Return On Capital Employed | (0.17) | (0.18) | |
Return On Assets | (0.13) | (0.13) | |
Return On Equity | (0.15) | (0.14) |
Management Efficiency
The value of Return On Tangible Assets is estimated to slide to -0.18. The value of Return On Capital Employed is expected to slide to -0.18. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.8 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Last Reported | Projected for Next Year | ||
Book Value Per Share | 14.60 | 8.66 | |
Tangible Book Value Per Share | 10.22 | 7.20 | |
Enterprise Value Over EBITDA | (10.99) | (11.54) | |
Price Book Value Ratio | 1.48 | 1.55 | |
Enterprise Value Multiple | (10.99) | (11.54) | |
Price Fair Value | 1.48 | 1.55 | |
Enterprise Value | 223.1 M | 198.4 M |
Understanding the operational decisions made by Castle Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin 0.0592 | Profit Margin 0.0195 | Beta 0.985 | Return On Assets (0) | Return On Equity 0.0147 |
Technical Drivers
As of the 20th of December, Castle Biosciences shows the Mean Deviation of 2.44, risk adjusted performance of (0.02), and Standard Deviation of 3.29. Castle Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Castle Biosciences market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Castle Biosciences is priced correctly, providing market reflects its regular price of 27.09 per share. Given that Castle Biosciences has information ratio of (0.05), we suggest you to validate Castle Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.Castle Biosciences Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Castle Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Castle Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Castle Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Castle Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Castle Biosciences Outstanding Bonds
Castle Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Castle Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Castle bonds can be classified according to their maturity, which is the date when Castle Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Castle Biosciences Predictive Daily Indicators
Castle Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Castle Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 14546.53 | |||
Daily Balance Of Power | 0.5044 | |||
Rate Of Daily Change | 1.02 | |||
Day Median Price | 27.07 | |||
Day Typical Price | 27.07 | |||
Price Action Indicator | 0.31 | |||
Period Momentum Indicator | 0.57 |
Castle Biosciences Corporate Filings
F4 | 19th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 17th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 9th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Castle Biosciences Forecast Models
Castle Biosciences' time-series forecasting models are one of many Castle Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Castle Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Castle Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Castle Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Castle shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Castle Biosciences. By using and applying Castle Stock analysis, traders can create a robust methodology for identifying Castle entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.26) | (0.27) | |
Operating Profit Margin | (0.31) | (0.32) | |
Net Loss | (0.26) | (0.27) | |
Gross Profit Margin | 0.80 | 0.63 |
Current Castle Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Castle analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Castle analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
33.0 | Strong Buy | 9 | Odds |
Most Castle analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Castle stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Castle Biosciences, talking to its executives and customers, or listening to Castle conference calls.
Castle Stock Analysis Indicators
Castle Biosciences stock analysis indicators help investors evaluate how Castle Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Castle Biosciences shares will generate the highest return on investment. By understating and applying Castle Biosciences stock analysis, traders can identify Castle Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow | 122.9 M | |
Common Stock Shares Outstanding | 26.8 M | |
Total Stockholder Equity | 391.3 M | |
Tax Provision | 119 K | |
Quarterly Earnings Growth Y O Y | -0.926 | |
Property Plant And Equipment Net | 37.7 M | |
Cash And Short Term Investments | 243.1 M | |
Cash | 98.8 M | |
Accounts Payable | 10.3 M | |
Net Debt | -83.5 M | |
50 Day M A | 31.1652 | |
Total Current Liabilities | 47.7 M | |
Other Operating Expenses | 287.8 M | |
Non Current Assets Total | 157.7 M | |
Non Currrent Assets Other | 2.6 M | |
Stock Based Compensation | 51.2 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.